6949 Peil Biomedical: Announcement Regarding Change in R&D Leadership
Peil Biomedical (6949) announced on May 20 a leadership change in its R&D department. The Deputy R&D Head Lin Wei-Chi has resigned, with R&D Division Head Lin Ren-Jie appointed as interim replacement.
📋 Article Processing Timeline
- 📰 Published: May 21, 2026 at 06:31
- 🔍 Collected: May 21, 2026 at 06:31 (0 min after Published)
- 🤖 AI Analyzed: May 21, 2026 at 10:15 (3h 43m after Collected)
Announcement Date: 2026/05/21
Statement Date: 2026/05/20
Statement Time: 14:57:01
Company Code: 6949
Company Name: Peil Biomedical
Subject: Announcement regarding the change of the company's R&D leadership
Compliance Clause: Article 8
Date of Event: 2026/05/20
Explanation:
1. Personnel change category: R&D leadership
2. Date of change: 2026/05/20
3. Name, title, and profile of the outgoing person: Lin Wei-Chi / Deputy Head of R&D at the company
4. Name, title, and profile of the incoming person: Lin Ren-Jie (Interim) / Head of R&D division at the company
5. Type of change: Resignation
6. Reason for change: Personal career planning
7. Effective date: 2026/05/20
8. Other notes: None
Statement Date: 2026/05/20
Statement Time: 14:57:01
Company Code: 6949
Company Name: Peil Biomedical
Subject: Announcement regarding the change of the company's R&D leadership
Compliance Clause: Article 8
Date of Event: 2026/05/20
Explanation:
1. Personnel change category: R&D leadership
2. Date of change: 2026/05/20
3. Name, title, and profile of the outgoing person: Lin Wei-Chi / Deputy Head of R&D at the company
4. Name, title, and profile of the incoming person: Lin Ren-Jie (Interim) / Head of R&D division at the company
5. Type of change: Resignation
6. Reason for change: Personal career planning
7. Effective date: 2026/05/20
8. Other notes: None
FAQ
What happened to the R&D department at Peil Biomedical?
There was a leadership change in the R&D department; the incumbent resigned, and the head of the R&D division is acting as the interim replacement.
Who is the new R&D head?
It is not a permanent appointment at this time; Lin Ren-Jie, the R&D division head, is serving as the interim.
Will this transition affect operations?
The departure is due to personal reasons, and there are no signs of organizational issues, suggesting standard operational continuity.